FSDC Share Price | Disc Medicine, Inc. Stock Analysis & Recommendation

Q: Is Disc Medicine, Inc. technically bullish or bearish?

As of 8 September 2025, the technical trend for Disc Medicine, Inc. has changed from mildly bullish to bullish. The current stance is bullish with strong indicators supporting this view. The MACD is bullish on both the weekly and monthly time frames, and Bollinger Bands are also bullish across both periods. The daily moving averages confirm a bullish trend as well. However, the RSI shows a bearish signal on the monthly timeframe, and the KST indicates a mildly bearish stance monthly, while Dow Theory presents a mixed view with mildly bearish weekly and mildly bullish monthly signals.In terms of performance, Disc Medicine has outperformed the S&P 500 over the past year with a return of 31.44% compared to the S&P's 17.14%, and significantly over the past three years with a return of 353.84% versus 70.41%. However, it has underperformed over the year-to-date and five-year periods.

Q: What does Disc Medicine, Inc. do?

Overview: Disc Medicine, Inc. is a blank check company focused on effecting a merger or similar business combination within the biotechnology sector, classified under the Pharmaceuticals & Biotechnology industry and categorized as a micro-cap company.Financial Snapshot: Most recent Net Profit: -34 Million (Quarterly Results - Mar 2025) Market cap: USD 1,733.45 Million (Micro Cap) Key Metrics: P/E: NA (Loss Making) Industry P/E: NA Dividend Yield: 0.00% Debt Equity: -1.01 Return on Equity: -17.64% Price to Book: 2.62 Contact Details: Address: C/O Foresite Capital, 600 Montgomery St, Suite 4500 SAN FRANCISCO CA : 94111 Tel: 1 415 8774887 Fax: 1 302 6365454

Price Point

High/Low

1Day

52 Week

Valuation

Technical

Day's Volume

CASH

94.86 k

Shareholding (Mar 2026)

FII

10.31%

Held by 98 FIIs

DII

70.22%

Held by 46 DIIs

Promoter

19.47%

Is Disc Medicine, Inc. technically bullish or bearish?

20-Sep-2025

As of September 8, 2025, Disc Medicine, Inc. is in a bullish trend with strong indicators, despite mixed signals from the RSI and KST, and has outperformed the S&P 500 over the past year and three years, but underperformed year-to-date and over five years.

View full answer

How big is Disc Medicine, Inc.?

22-Jun-2025

As of Jun 18, Disc Medicine, Inc. has a market capitalization of 1,733.45 million and reported net sales of 0.00 million with a net profit of -116.50 million over the last four quarters. As of Dec 24, the company has shareholder's funds of 443.59 million and total assets of 496.77 million.

View full answer

What does Disc Medicine, Inc. do?

22-Jun-2025

Disc Medicine, Inc. is a blank check company targeting mergers in the biotechnology sector, currently reporting a net loss of $34 million and a market cap of approximately $1.73 billion. It has no dividend yield and negative return on equity.

View full answer

Compare Disc Medicine, Inc. with Similar Stocks

Aurinia Pharmaceuticals, Inc.Iovance Biotherapeutics, Inc.Twist Bioscience Corp.

Score

Click here to find our call on this stock

Strong Sell

Sell

Hold

Buy

Strong Buy

Dashboard

Unrated Stock - No Analysis Available

Mojo Parameters

Stock DNA

Industry

Pharmaceuticals & Biotechnology

Market cap

USD 2,293 Million (Small Cap)

P/E

NA (Loss Making)

Industry P/E

Dividend Yield

0.00%

Debt Equity

-1.03

Return on Equity

-28.68%

Price to Book

3.10

Revenue and Profits:

Net Sales:

(Quarterly Results - Mar 2026)

Net Profit:

-64 Million

Total Returns

Total Returns (Price + Dividend)

TimePeriod

Price Return

Dividend Return

Total Return

3 Months

1.62%

6 Months

-27.57%

1 Year

26.72%

2 Years

69.31%

3 Years

47.19%

4 Years

348.33%

5 Years

-44.88%

Disc Medicine, Inc. for the last several years.

Risk Adjusted Returns v/s

News & Corporate Actions

News

No Recent News for the Company

Announcements

No announcement available

Corporate Actions

No corporate action available

Key Factors

Quality key factors

Factor

Value

Sales Growth (5y)

EBIT Growth (5y)

-208.88%

EBIT to Interest (avg)

-70.07

Debt to EBITDA (avg)

Negative Net Debt

Net Debt to Equity (avg)

-1.01

Sales to Capital Employed (avg)

Tax Ratio

0.40%

Dividend Payout Ratio

Pledged Shares

Institutional Holding

100.00%

ROCE (avg)

ROE (avg)

Valuation key factors

Factor

Value

P/E Ratio

NA (Loss Making)

Industry P/E

Price to Book Value

3.10

EV to EBIT

-6.49

EV to EBITDA

-6.50

EV to Capital Employed

-71.05

EV to Sales

PEG Ratio

Dividend Yield

ROCE (Latest)

Negative Capital Employed

ROE (Latest)

-28.68%

Technicals key factors

Indicator

Weekly

Monthly

MACD

Bearish

Bullish

RSI

No Signal

Bollinger Bands

Mildly Bearish

Bullish

Moving Averages

Mildly Bearish (Daily)

KST

Bearish

Mildly Bearish

Dow Theory

Mildly Bullish

Mildly Bearish

OBV

Mildly Bullish

Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned

Shareholding

Shareholding Snapshot : Mar 2026

Shareholding Compare (%holding)

Majority shareholders

Domestic Funds

Held in 52 Schemes (41.11%)

Foreign Institutions

Held by 98 Foreign Institutions (10.31%)

Strategic Entities with highest holding

Highest Public shareholder

Financial

[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "header": "Quarterly Results Snapshot (Consolidated) - Mar'26 - YoY",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in quarter ended Mar 2026 is 0.00% vs 0.00% in Mar 2025",
        "dir": 0
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in quarter ended Mar 2026 is -86.22% vs -26.77% in Mar 2025",
        "dir": -1
      }
    ],
    "table": {
      "header": [
        "Mar'26",
        "Mar'25",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-69.40",
          "val2": "-39.90",
          "chgp": "-73.93%",
          "chgp_class": "negative"
        },
        {
          "field": "Interest",
          "val1": "0.80",
          "val2": "0.90",
          "chgp": "-11.11%",
          "chgp_class": "positive"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-63.50",
          "val2": "-34.10",
          "chgp": "-86.22%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "0.00%",
          "val2": "0.00%",
          "chgp": "NA",
          "chgp_class": "neutral"
        }
      ]
    }
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Consolidated) - Dec'25",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in year ended Dec 2025 is 0.00% vs 0.00% in Dec 2024",
        "dir": 0
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in year ended Dec 2025 is -93.97% vs -43.19% in Dec 2024",
        "dir": -1
      }
    ],
    "table": {
      "header": [
        "Dec'25",
        "Dec'24",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-235.70",
          "val2": "-129.60",
          "chgp": "-81.87%",
          "chgp_class": "negative"
        },
        {
          "field": "Interest",
          "val1": "3.60",
          "val2": "0.60",
          "chgp": "500.00%",
          "chgp_class": "negative"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-212.20",
          "val2": "-109.40",
          "chgp": "-93.97%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "0.00%",
          "val2": "0.00%",
          "chgp": "NA",
          "chgp_class": "neutral"
        }
      ]
    }
  }
]

Quarterly Results Snapshot (Consolidated) - Mar'26 - YoY

Mar'26

Mar'25

Change(%)

Net Sales

0.00

Operating Profit (PBDIT) excl Other Income

-69.40

-39.90

-73.93%

Interest

0.80

0.90

-11.11%

Exceptional Items

0.00

Consolidate Net Profit

-63.50

-34.10

-86.22%

Operating Profit Margin (Excl OI)

0.00%

USD in Million.

Compare with Peers

Net Sales

YoY Growth in quarter ended Mar 2026 is 0.00% vs 0.00% in Mar 2025

Consolidated Net Profit

YoY Growth in quarter ended Mar 2026 is -86.22% vs -26.77% in Mar 2025

All Quarterly Results

Annual Results Snapshot (Consolidated) - Dec'25

Dec'25

Dec'24

Change(%)

Net Sales

0.00

Operating Profit (PBDIT) excl Other Income

-235.70

-129.60

-81.87%

Interest

3.60

0.60

500.00%

Exceptional Items

0.00

Consolidate Net Profit

-212.20

-109.40

-93.97%

Operating Profit Margin (Excl OI)

0.00%

USD in Million.

Compare with Peers

Net Sales

YoY Growth in year ended Dec 2025 is 0.00% vs 0.00% in Dec 2024

Consolidated Net Profit

YoY Growth in year ended Dec 2025 is -93.97% vs -43.19% in Dec 2024

All Annual Results

Company CV

About Disc Medicine, Inc.

Disc Medicine, Inc.

Pharmaceuticals & Biotechnology

FS Development Corp. is a blank check company. The Company is formed for the purpose of effecting a merger, capital stock exchange, asset acquisition, stock purchase, reorganization or similar business combination with one or more businesses. The Company focuses for target business in the biotechnology sector. The Company has no business operations and has not generated any revenues.

Company Coordinates

Company Details

C/O Foresite Capital, 600 Montgomery St, Suite 4500 SAN FRANCISCO CA : 94111

Tel: 1 415 8774887

Registrar Details